School of Chemistry and Chemical Engineering, Shanxi University, Taiyuan, 030006, China.
Angew Chem Int Ed Engl. 2021 Jun 1;60(23):12992-12998. doi: 10.1002/anie.202102377. Epub 2021 Apr 29.
Discrimination of cancer cells/tissues from normal ones is of critical importance for early diagnosis and treatment of cancers. Herein, we present a new strategy for high-contrast fluorescence diagnosis of cancer cells/tissues based on β-Lapachone (β-Lap, an anticancer agent) triggered ROS (reactive oxygen species) amplification specific in cancer cells/tissues. With the strategy, a wide range of cancer cells/tissues, including surgical tissue specimens harvested from patients, were distinguished from normal ones by using a combination of β-Lap and a Si-rhodamine-based NIR fluorescent ROS probe PSiR3 developed in this work with average tumor-to-normal (T/N) ratios up to 15 in cell level and 24 in tissue level, far exceeding the clinically acceptable threshold of 2.0. What's more, the strategy allowed the fluorescence discrimination of tumor tissues from inflammatory ones based on whether a marked fluorescence enhancement could be induced when treated with PSiR3 and β-Lap/PSiR3 combination, respectively.
区分癌细胞/组织与正常细胞/组织对于癌症的早期诊断和治疗至关重要。在此，我们提出了一种基于β-拉帕醌（β-Lap，一种抗癌药物）触发的针对癌细胞/组织的 ROS（活性氧）放大的新策略，用于高对比度荧光诊断癌细胞/组织。通过该策略，使用β-Lap 和我们在此工作中开发的基于 Si-罗丹明的近红外荧光 ROS 探针 PSiR3 的组合，可将包括从患者中采集的手术组织标本在内的多种癌细胞/组织与正常细胞/组织区分开来，在细胞水平上的平均肿瘤与正常（T/N）比值高达 15，在组织水平上高达 24，远远超过临床可接受的 2.0 阈值。更重要的是，该策略允许基于用 PSiR3 和β-Lap/PSiR3 组合处理时是否可以诱导明显的荧光增强，来区分肿瘤组织和炎症组织。
